Efficacy and Safety of the ELIOS Laser in Combined Cataract and Glaucoma Surgery

Recruiting now · Not applicable

Conditions studied: Glaucoma

In brief

Glaucoma is an irreversible optic neuropathy. It is the second most common cause of blindness worldwide. Glaucoma can be treated with topical medications (eye drops), laser or surgery. Traditional surgery is invasive and has a high complication rate (hypotonia, endophthalmitis, cataracts, etc.). As a result, several types of micro-invasive surgery (MIGS) have been developed to reduce the risks of surgery while maintaining their effectiveness in lowering intraocular pressure (IOP). The ELIOS laser system is the only ophthalmological excimer laser designed for the surgical treatment of glaucoma. The aim of the procedure is to ablate the trabecular meshwork and inner wall of Schlemm´s canal ab interno, with the creation of 10 microchannels of 210 um in the trabeculum using the ELIOS laser with a wavelength of 308 nm, in order to improve trabecular outflow to achieve a reduction in IOP. The ELIOS laser is an example of Microinvasive Glaucoma surgery (MIGS) with published results demonstrating efficacy and safety. The ELIOS laser is already in use in France (AMM / CE mark achieved). Its use as part of a prospective interventional study will enable us to collect data in order to treat patients more effectively and improve the quality of care provided to glaucoma patients.

Key facts

Study ID: NCT06760169
Run by: Hôpital Privé de la Baie
People needed: 46
Starts: 2025-01-05
Expected to finish: 2028-02-28
Last updated by the study team: 2026-04-01

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients ≥ 18 years of age who agree to take part in the study and have signed an informed consent form
Visually significant cataract with indication for surgery
Primary open-angle glaucoma, or secondary open-angle glaucoma (pseudoexfoliative glaucoma or pigmentary glaucoma) with indication for cataract surgery.
Open iridocorneal angle (Shaffer classification grade 2-4)
Early to moderate glaucoma (advanced glaucoma, with MD from VFs worse than -12dB, will be excluded)

You may not qualify if…

Presence of severe systemic pathologies 2024-A01891-46_Protocol_V6_21112024_Elios Page 20 / 58
Pregnant or breastfeeding women
<18 years of age
Presence of other ophthalmological pathologies (except cataracts), and exclusion of severe dry eye.
History of intraocular surgery, trauma, or conjunctival scarring in the quadrant intended for surgery
Visual acuity worse than "counting fingers".
Closure of the iridocorneal angle (and angle-closure glaucoma), angle-closure glaucoma secondary to iridocorneal synechiae, neovascular glaucoma or neovascularization of the iris.
Normal-pressure glaucoma
Pachymetry < 490 um or > 620 μm
Glaucomatous visual field with mean deviation worse than ≤-12 dB
IOP > 35 mmHg
Autoimmune disorder, especially collagenosis
Patient under protective supervision
Patient not covered by a social security scheme

Where it is running

Hôpital Privé de la Baie — Avranches, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.